BioCentury
ARTICLE | Clinical News

INNO 101 hepatitis C: Discontinued development

September 17, 2007 7:00 AM UTC

INNX discontinued development of HCV E1 vaccine after the compound missed the primary endpoint of a significant reduction in liver tissue damage vs. placebo in a Phase IIb trial (Study 918) in 122 pat...